Broadcast Date: June 9, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Engineering DNA to study changes in gene expression and cellular responses has been the mainstay of molecular biology research for decades. Yet, what if we extrapolated the standard concepts of DNA engineering and applied them to therapeutic antibody development for treating an array of diseases. If implemented successfully, this approach could open entirely new areas for drug discovery research. Recently, while utilizing exogenously synthesized plasmid DNA that encodes for human monoclonal antibodies, investigators have been able to produce the immuno-molecules that target therapeutic markers for life-threatening illnesses, such as cancer.

In this GEN webinar, we will hear from two members of the clinical development and discovery research teams at Inovio, a biotechnology company that designs and delivers DNA medicines. We will learn about the novel DNA-encoded monoclonal antibody (dMab™) technology and how it is being employed for cancer therapies. Additionally, our presenters will describe some current pre-clinical work using DNA-encoded immune cell engagers (DICE).

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

 

Produced with support from:

Sartorius logo

 

 

 

Jeffrey Skolnik

Jeffrey Skolnik, MD
Vice President,
Clinical Development
Inovio

Trevor Smith, PhD

Trevor Smith, PhD
Discovery Research, R&D
Inovio